IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Innovative Drug Delivery Approaches For Anti-Fungal Therapies: Formulation And Assessment Paradigms

[1]Vishakha P.Patil, [2]Smital Gondkar, [3]Ashwini Pagar [4]Shruti Joshi

[1-4] UG Student, Department of B Pharmacy Pravara College of Pharmacy (for Women's) Chincholi, Nashik, Maharashtra

[1]Mr.Vikas Kunde

[1]Assitant professor, Department of B Pharmacy Pravara College of Pharmacy (for Women's) Chincholi, Nashik

Abstract: Infection have emerged as a significant global health concern, particularly among individuals delivery methods is highlighted by the rise in antifungal resistance and the drawbacks of traditional formulations. The formulation of antifungal treatments is examined in this review, encompassing both traditional and novel systems. There includes a through discussion of important elements such solubility, permeability, stability, targeted delivery and patient adherence. The potential of novel platforms based on nanotechnology, including as liposomes, nanosponges, ethosomes and transdermal gels, to improve treatment results, increase safety, and reduce side effects is investigated.

Index Terms – Targeted Delivery, Patient Adherence, Permeability, Transdermal gels, Ethsomes, Liposomes.

I. INTRODUCTION

Greetings From minor ailments like tinea and candidiasis to serious systemic illnesses like aspergillosis, cryptococcosis, and mucormycosis, fungal infections can cause serious harm. These infections are especially harmful to immunocompromised people, such as those receiving immunosuppressive treatment and organ transplants, those with diabetes, cancer, or HIV/AIDS. Despite a significant increase in the frequency of fungal illnesses worldwide in recent decades, mortality rates are still high, primarily as a result of delayed diagnosis, few available treatments, and growing antifungal resistance. All of the main antifungal medication classes, such as azoles (like fluconazole), echinocandins (like capsafungin), and polyenes (like amphotericin B), have been found to exhibit resistance. Numerous antifungal drugs also have serious formulation issues, including low permeability, short half-lives, high systemic toxicity,and poor water solubility, all of which might jeopardise treatment compliance and safety.Drug delivery innovations such ethosomes, solid lipid nanoparticles (SLNs), liposomes, nanosponges, and nanoemulsions present encouraging alternatives. These systems can boost bioavailability, facilitate targeted and controlled release, improve permeability across biological barriers, and improve solubility. They could revolutionise antifungal treatment by lowering toxicity and frequency of administration.

II. TOPICAL FORMULATION

1. Creams: Creams are emulsions of water and oil; they are typically made as oil inwater (O/W) for antifungal purposes because of their easy application, non-greasy texture, and aesthetic appeal. Because water-in-oil (W/O) creams have more occlusive qualities, they are heavier and more appropriate for extremely dry, scaly skin. Principal benefits of antifungal treatment: Provide elevated local drug levels with negligible systemic impacts. Give sore or inflamed skin calming, hydrating comfort. Especially useful in moist regions (underarms, skin folds, groin) where powders or gels are less appropriate. A pleasant experience increases patient compliance.

For instance:

a. Clotrimazole cream is a broad spectrum azole that fights candida and dermatophytes. b. Terbinafine cream is an allylamine that inhibits dermatophytes.

Common applications include cutaneous candidiasis, intertrigo, tinea corporis, and tinea cruris. Formulation consideration include adjusting the PH (4.5-6.5) to correspond with skin physiology, using humectants to improve hydration and penetration, and using preservative to prevent contamination.

2. Ointments: Oil-based semisolids known as ointments are created from hydrophobic bases such as lanolin, paraffin, or petroleum oil. They provide a powerful occlusive barrier that softens skin, prevents water loss, and improves drug absorption into deeper layers. Principal benefits of antifungal treatment: For a sustained release, keep your skin in touch for a long time. Strong emollient action aids in barrier function restoration. stable for

medications that react to dampness. Reapplication is less frequent than with water-based systems.

- Restrictions: they frequently have a greasy feel that might discolour clothing and are not recommended for damp or folded skin (may induce maceration).

Example:

Nystatin ointment is an example of an effective treatment for Candida infections. For persistent dermatophyte infections, Whitfield's ointment combines keratolytic and antifungal ingredients.

3. **Lotions**: Suitable for application over large or hair-bearing areas where heavier preparations may be difficult, lotions are low- viscosity, water based or hydroalcoholic liquids that spread readily and dry rapidly.Because of their light texture, which prevents occlusion and permits skin ventilation, they are especially advantageous for inflammatory or exudative lesions.

Their non-greasy finish enhances patient comfort in hot, muggy weather.

Examples:

include Ciclopirox lotion and Econazole lotion.

Uses include pityriasis versicolour, seborrhoeic dermatitis, and tinea capitis (as a supplement to oral therapy).

Formulation notes: To preserve consistency and reduce skin dryness, it is frequently stabilised with humectants such glycerin and surfactants

4. Solution: The medicine is completely dissolved in solutions, which are transparent liquid formulations that guarantee even dispersion and improved penetration into nails and hair

follicles. They are useful for infections of the scalp and nails because of their thin consistency, which allows access to confined areas. Although they may sting, alcohol-based versions also help dry damp lesions and have a modest antiseptic effect.

Examples:

Terbinafine solution and amorolfine solution.

Uses include onychomycosis and tinea capitis (when treated with oral antifungals). Formulation notes: To increase penetration, common solvents include propylene glycol, ethanol, and isopropanol. The effectiveness of nail treatments may be enhanced by occlusive coverings.

5. **Sprays (Pump or Aerosol)**: Antifungal chemicals are dispersed as a fine mist by sprays, making it simple to cover broad or difficult-to-reach areas without coming into direct contact with the skin. They are very useful for the back, groin, and feet. while powder Based sprays combine moisture management and antifungal action, alcohol Based sprays provide a chilling feeling and help dry lesions.

Example:

Terbinafine and tolnaftate sprays

Applications include prevention in social or sporting contexts, jock itch, and athlete's foot. Formulation notes: Pump sprays are safer for kids and people with sensitive skin, whereas aerosols should be handled carefully to prevent inhalation.

6. **Powders:** Antifungal agents are combined with absorbent carriers such talc, starch, or zinc oxide to create powders. They aid in regulating moisture, lowering friction, and establishing an atmosphere that is not conducive to the growth of fungi. Commonly used for both prevention and treatment, particularly in people who live in warm, humid areas or are prone to recurring infections.

Examples:

Miconazole powder

Uses include prevention of skin folds, tinea pedis, and tinea cruris. Notes on formulation: Both medicated and non-medicated variants are available; in humid environments, the finer particle size guarantees improved adherence

7.Shampoo: Antifungal shampoos treat fungal infections of the scalp and hair by combining cleaning surfactants with active antifungal ingredients. In order to provide adequate medication contact time, these formulations should be massaged into the scalp and left there for a few minutes before being rinsed.

For instance: Shampoo containing ketoconazole and selenium sulphate. Typical Applications: Seborrhoeic dermatitis and tinea capitis

8.Gels: Gels are semi-solid formulations that provide effective drug penetration and a pleasant cooling sensation. They have an aqueous or hydroalcoholic foundation. They are perfect for applying to areas with hair or moist lesions because they are non-greasy, unlike ointments.

For instance: Common Applications for Terbinafine Gel: Fungal scalp infections and tinea corporis.

9.lacquers for nails: In order to ensure localised administration of antifungal drugs for the treatment of onychomycosis, nail lacquers are specialised topical solutions made to penetrate the dense keratin matrix of nails. For full therapeutic effects, they must be used consistently over an extended period of time.

For instance: Amorolfine lacquer with ciclopirox lacquer.

III. Mucosal formulation

1.Oral Solutions and Suspensions: There are two applications for these liquid formulations:

A.For localised oral infections, "swish and spit.''

B.For esophageal and oropharyngeal candidiasis, "swish and swallow."

They increase the amount of time the medication is in contact with the mucosal surfaces, which is particularly advantageous for individuals who have trouble swallowing solid dosage forms.

Nystatin oral suspension, for instance, is a polyene antifungal that works against Candida albicans without causing systemic absorption. A triazole antifungal with systemic absorption for more extensive therapeutic coverage is fluconazole oral suspension. Benefits include a high level of local concentration.

Limitations: Needs several doses per day, Compliance may be impacted by an unpleasant taste. Fluconazole may cause systemic adverse effects.

2.Pastilles, Lozenges, and Troches: For prolonged local action, the drug is released gradually from these solid forms as the dissolve slowly in the mouth.

For instance, clotrimazole lozenges can be used to treat oropharyngeal candidiasis, particularly in patients with weakened immune systems. For once-daily dosage, Miconazole buccal pills are adhered to the gum.

Benefits include: Extended duration of medication interaction, Beneficial for HIV or cancer prophylaxis.

Constraints: Needs cooperation from the patient, Dental caries may result from forms that contain sugar.

IV. Vaginal formulation

These provide high local concentrations with less systemic absorption in order to treat vulvovaginal candidiasis (VVC).

1.Vaginal cream: Emulsion based vaginal creams that are administered using an applicator. For instance, clotrimazole cream.

2.Inserts, pessaries, and suppositories: -solid or semi-solid materials that melt at body temperature. Miconazole nitrate suppositories and Clotrimazole pills are two examples.

3.Vaginal tablet: Compressed powders that dissolve in vaginal secretions are known as vaginal tablets. For instance, Terconazole vaginal pills.

4.Vaginal rings: Flexible sustained-release devices called vaginal rings are presently being researched for their potential antifungal use.

For instance, experimental clotrimazole or miconazole rings

V. Opthalmic formulation

1.Eye drops: It is sterile suspensions or solutions that are injected into the sac that surrounds the eyes.

- Examples include voriconazole eye drops (compounded) and a 5% suspension of natamycin.

2.Eye ointment: Greasy semi-solids that extend contact time are called eye ointments.

- For instance, compounded amphotericin B ointment.
- Benefits include: Long-lasting release; Less frequent dose than drops.
- Limitations: Vision blurring is possible, Compounding is frequently necessary, little commercial supply.

VI. Nano Techniques For antifungal Drug Delivery.

1.LIPOSOMES

Liposomes are vesicles which consist of one or more concentric lipid bilayers separated by water or aqueous buffer compartment, ranging in size from 10 nanometers to 20 micrometers. Liposomes were reported to interact with the skin via several mechanisms. They are either adsorbed onto the skin surface leading to the release of drugs, or penetrate via the lipid-rich channels either intact, or after losing some lipid lamellae; alternatively, they form occlusive films which increase skin hydration and drug penetration into the stratum corneum. Regarding their applications in fungal infections, a liposomal gel of ketoconazole allowed more drug retention in the skin compared to the gel and cream formulations. They were also reported to increase both the deposition and skin permeation of fluconazole when compared to controls, and enhance its therapeutic effectiveness against cutaneous candidiasis. Liposomes were also able to effectively decrease fungal colonies when encapsulating ciclopirox olamine. Prolongation of the action of terbinafine was also suggested by the other authors upon encapsulating into liposomal gels. Liposomes of croconazole too showed excellent activity against different fungal species when compared to miconazole cream as a control.

2.Nanostructured Lipid Carriers (NLCs) and Solid Lipid Nanoparticles (SLNs): Solid lipid nanoparticles are carriers in which the drug is entrapped within a solid lipid core matrix. Examples of these lipids are triglycerides, diglycerides, monoglycerides, fatty acids, steroids, and waxes.[16] Nanostructured lipid carriers are the second generation of lipid nanoparticles in which the matrix is composed of a mixture of solid and liquids lipids. Among the advantages of lipid nanoparticles are that the lipids utilized in their preparation are physiological lipids and that can prepared using organic solvent-free methods. Both solid lipid nanoparticles and nanostructured lipid carriers have been recommended as good carriers for the treatment of topical skin infections, especially for antifungal drugs which as known to be lipophilic, and hence, can be successfully entrapped within the lipidic core of solid lipid nanoparticles or nanostructured lipid carriers.

3.Niosomes

Niosomes are similar to liposomes, they only differ in the replacement of phospholipids with non - ionic surfactant. Upon topical application, they interact with the stratum corneum leading to a reduction of transepidermal water loss. Similar lipsomes, they are either adsorbed on the surface of the skin leading to high thermodynamic activity gradient of the drug at the interface which facilitates drug permeation, or they penetrate into the stratum corneum themselves and act as a drug reservoir. Regarding their applicability in the treatment of fungal infection, griseofulvin niosomes incorporated in gel showed high mycological cure rates of about 80% in patient suffering from tinea corporis. Terbinafine hydrochloride niosoms showed efficacy against aspergillus niger. The action of ketoconazole was prolonged by encapsulating it into niosomes.Niosomes of itraconazole and miconazole were also found to be effective, proving themselves to be effective carrier systems of antifungal drugs.

4.Metallic and Polymeric Nanoparticles :- Metallic nanoparticles (like silver and gold) may possess inherent antifungal properties, whereas polymeric nanoparticles (like PLGA and chitosan) offer continuous release.

Benefits include: Prevent medication deterioration, Enhance tissue penetration and cellular uptake, Lower dosage frequency.

For instance, chitosan nanoparticles containing miconazole provide enhanced antifungal efficacy and delayed release.

5.Mucoadhesive Systems and Hydrogels In order to extend drug contact, mucoadhesive systems stick to mucosal surfaces and hydrogels are networks of water-rich polymers.

Benefits include: Improving patient compliance by continuous release, Increasing local medication concentration with little systemic absorption.

For instance: when compared to conventional gels, mucoadhesive clotrimazole gels offer superior

therapeutic results for oral candidiasis.

6.Microemulsions and Microsponges:

Microemulsions are defined as thermodynamically Stable mixtures of oil and water stabilized by surfactants and co-surfactants, with size in the nanometer range. Owing to their ability to solubilize many poorly Soluble drugs, microemulsions have been found very Promising in the delivery of antifungal drugs which are characterized by their lipophilicity. A microemulsion gel developed for topical delivery of fluconazole for the treatment of invasive fungal Infections was developed and found very effective in enhancing percutaneous absorption of the Drug. Several researchers further confirmed the ability of microemulsions to increase percutaneous in enhancing percutaneous absorption of the drug. Several researches further confirmed the drug. Several researches further confirmed the ability of microemulsions to increase percutaneous permeability of fluconazole. The same results in enhancing percutaneous absorption of the drug. Several researches further confirmed the ability of microemulsion to increase percutaneous permeability of fluconazole. The same results were obtained with microemulsion formulae of ketoconazole, itraconazole, voriconazole and econazole. Microemulsion based hydrogels of clotrimazole exhibited higher skin retention and higher in vitro activity against C. albicans when compared to the conventional cream. Furthermore, It demonstrated clinical efficacy when tested in patients suffering from tinea corporis, tinea circinata and tinea pedis with skin involvement of <10% of the total body surface area. A microemulsion based hydrogels of sertaconazole showed 3-fold higher skin retention than the commercial cream, with higher in vitro antifungal activity against C. albicans. Amphotericin was also incorporated in microemulsion form for treatment of invasive fungal infections in which a 2-fold increase in skin retention was obtained with the microemulsion formulation compared to the plain drug solution, with better in vitro antifungal activity against trichophyton rubrum. Moreover, microemulsion formulation of griseofulvin caused complete resolution of dermatophytosis in 7 days.

7.Dendrimers: Dendrimers are artificial macromolecules with several functional groups for drug attachment that are extremely branched and nanoscale.

Benefits include: Improved bioavailability, stability, and solubility, Enables controlled and targeted release.

For instance: PAMAM dendrimers greatly enhance the antifungal activity and solubility of ketoconazole.

VII. Challenges in antifungal drug formulation

Difficulties in Formulating Antifungal Drugs Numerous pharmacological, biological, and clinical obstacles impede the creation of efficacious antifungal compositions. These challenges may diminish treatment adherence, jeopardise patient safety, and limit the effectiveness of medications. Designing sophisticated and focused delivery methods requires an understanding of these difficulties.

1. **Solubility in Water:** Due to their extremely low water solubility, many antifungal medications—especially azoles and polyenes—dissolve poorly in physiological fluids and have a lower bioavailability. High quantities of surfactants or organic solvents are frequently required for this, which may result in systemic toxicity or local irritation.

For instance: the solubility problems of itraconazole lead to variable absorption, necessitating formulation using lipid-based systems or cyclodextrins.

2.Limited Permeability: When treating infections at hard-to-reach locations, a drug's capacity to penetrate biological barriers—such as the skin, mucosa, or blood–brain barrier—is crucial. Since many antifungals have low permeability, they are less effective against infections that are deeply rooted.

For instance, amphotericin B's ability to pass across biological membranes is restricted by its enormous molecular weight and hydrophobic properties.

3.Stability issues: Antifungal medications may lose their effectiveness while being stored if they are exposed to heat, light, or moisture. To sustain therapeutic action, formulation techniques need to take chemical and physical stability into account.

For instance, natamycin needs light-protective packaging since it is prone to photodegradation.

4.Systemic toxicity: clinical use of several strong antifungals may be restricted due to their severe adverse effects.

For instance, despite its great efficacy, amphotericin B is well-known for its nephrotoxicity, electrolyte imbalances, and symptoms connected to infusion. One of the main formulation goals is to reduce systemic exposure through tailored delivery systems.

5.Interactions between Drugs and Excipients: Cytochrome P450 enzymes metabolise antifungal medications, especially azoles, and they cancombine with other drugs to change the effectiveness of treatment. Certain excipients may also have an impact on the stability or absorption of drugs.

For instance, itraconazole suppresses CYP3A4, which raises the plasma levels of medications taken together, such as some statins, and may be hazardous.

6.Development resistance: The long-term effectiveness of treatment can be decreased by selecting for resistant fungus strains by inappropriate or prolonged usage of antifungals. Resistance may also be exacerbated subtherapeutic dosage or poor medication uptake.

For instance, there is growing evidence of fluconazole resistance in Candida albicans in patients with weakened immune systems

VIII. Strategies to overcome formulation challenge

Techniques for Solving Formulation Issues innovative formulation techniques that increase permeability, decrease toxicity, improve solubility, and boost patient compliance can help overcome the drawbacks of traditional antifungal treatments. To maximise therapeutic performance, these tactics combine cutting-edge drug delivery technologies with astute excipient selection.

1.Improving Solubility

Liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and polymeric nanoparticles are examples of nanotechnology-based carriers that can encapsulate poorly soluble antifungals to improve their solubility and bioavailability.

Complexes increase water solubility by forming inclusion complexes with hydrophobic medications.

Lipid-based formulations that improve solubilisation in the gastrointestinal tract include microemulsions and self-emulsifying drug delivery systems (SEDDS).

For instance, itraconazole–cyclodextrin complexes decrease dosage variability and enhance oral absorption.

2.Enhancing Permeability

Ethanol, oleic acid, and surfactants are examples of penetration enhancers that improve skin and mucosal penetration.Drugs can be delivered to deeper tissues using nanoscale carriers that can get past biological barriers.Targeted delivery systems direct antifungals to infected locations using ligands or antibodies.

For instance, voriconazole-loaded nanoemulsions improve corneal penetration in the treatment of fungal keratitis

3.**MITIGATING SYSTEMIC HAZARDS**

Drug exposure to healthy tissues is reduced via targeted delivery.Sustained-release methods steer clear of peaks that could have negative consequences while maintaining therapeutic levels. By changing biodistribution, lipid-based carriers lessen the toxicity of medications such as amphotericin B.

for instance,liposomal amphotericin B reduces kidney damage by preferentially delivering the medication to sick tissues.

4.REDUCING INTERACTIONS BETWEEN DRUGS AND EXCIPIENTS

Compatibility with active medications is ensured by careful excipient selection. Cytochrome P450-mediated interactions can be decreased by taking advantage of other metabolic pathways. by lowering peak plasma levels, controlled-release devices can lessen the chance of interactions.

For instance, slow-release itraconazole formulations lessen CYP3A4mediated medication interactions.

5.OVERCOMING OPPOSITION

To target several fungal pathways, combination therapy combines antifungals with adjuvants or other antifungals.

Controlled drug release ensures extended therapeutic exposure, lowering the possibility of sub-therapeutic doses; nanocarrier-based methods can improve medication uptake into resistant fungal cells.

For instance, fluconazole formulations in lipid nanoparticle form have demonstrated enhanced efficacy against resistant strains of Candida.

IX. Regulatory and manufacturing challenges

Challenges in Manufacturing and Regulation creating and introducing antifungal medication formulations to the market requires negotiating a challenging array of legal and production limitations. These difficulties may raise expenses, postpone the release of the product, and compromise the drug's ultimate quality.

1. Regulatory Conditions: To prove safety, efficacy, and quality, regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) want thorough preclinical and clinical evidence. Because their long-term safety profiles may not be as well established, novel delivery systems— such as liposomes or nanoparticles—frequently come under closer investigation.

For instance, even though liposomal amphotericin B was already being used in clinical settings, it required number of safety and pharmacokinetic investigations prior to licensure.

2.Standardisation and Quality Assurance: Consistently manufacturing advanced antifungal compositions might be challenging. Efficacy and safety may be impacted by variations in drug loading, particle size, and release characteristics. Ensuring batch-to-batch homogeneity requires strict adherence to Good Manufacturing Practices (GMP).

Example: To ensure stability during manufacture, solid lipid nanoparticles need exact temperature control.

3.Shelf-Life and Stability: Stability testing is essential since many antifungal compositions are sensitive to moisture, light, and temperature. Products that are unstable may lose their effectiveness before they expire, which would reduce their commercial viability.

For instance, in order to preserve droplet size and avoid phase separation, certain nanoemulsions need to be refrigerated.

4.Cost: Because they require specialised equipment, raw materials, or processing stages, cutting-edge delivery systems might be costly to develop. It might be especially difficult to scale up from lab to industrial production without sacrificing quality.

For instance, sterile filtering and high-pressure homogenisation are necessary for the commercial production of liposomes, and they can be expensive.

5.Market competition and intellectual property: It might be difficult to patent new formulations, particularly if the active pharmaceutical ingredient (API) is currently unprotected. Additionally, a new formulation's commercial life may be limited by competition from generic medicines.

For instance, despite increased bioavailability, reformulated itraconazole medicines are still up against less expensive generics.

X. Future perspective

Prospects for the Future antifungal treatment's future depends on combining cutting-edge medication delivery technologies with creative therapeutic strategies. Liposomes, dendrimers, and polymeric nanoparticles are examples of nanotechnology-based carriers that are anticipated to be crucial in enhancing solubility, permeability, and targeted distribution. These approaches may be used in conjunction with molecular-level developments like stimuli responsive carriers and ligand-targeted formulations to minimise systemic toxicity and enable precision delivery to infected regions. The design of antifungal formulations is also expected to be influenced by personalised medicine. By customising medication choice, dose, and delivery to a patient's genetic profile, physicians can increase therapeutic efficacy while lowering side effects. By forecasting drug-excipient interactions, stability, and patient-specific reactions, artificial intelligence (AI) and machine learning may further speed up formulation optimisation. A burgeoning field involves the utilisation of combination nanocarrier systems that co-deliver antifungals alongside immunomodulators or resistance-modifying drugs. This strategy might improve the host's immune response to fungal infections and tackle the rising problem of medication resistance. However, overcoming manufacturing, economic, and regulatory obstacles will be necessary to bring these discoveries from research to clinical practice.

XI. Conclusion

The formulation design has a major impact on the effectiveness of antifungal medication. Even though many superficial and systemic illnesses can still be treated with conventional formulations, their drawbacks—such as poor solubility, low permeability, toxicity, and the development of resistance—highlight the necessity for ongoing innovation. Novel medication delivery methods have already shown notable gains in patient adherence, safety, and efficacy. These include lipid-based carriers, nanoparticles, and mucoadhesive platforms. The main goals of ongoing research should be to meet strict regulatory requirements, optimise these systems for large-scale manufacturing, and guarantee long-term stability. Modern diagnostic and therapeutic techniques can be combined with sophisticated formulation techniques to create safer, more potent antifungal medications that satisfy the needs of a changing clinical environment .

XII. References

1. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. N Engl J Med. 2010;362(12):1119–1131.

2. Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(3): S445-S451.

3. Revie NM, Iyer KR, Robbins N, Cowen LE. Antifungal drug resistance: evolution, mechanisms and

impact. Curr Opin Microbiol. 2018;45:70–76.

4. Uppuluri P, Nett J, Heitman J, Andes D. Mechanisms of drug resistance in Candida albicans biofilms. Future Microbiol. 2010;5(6):835-847

5. Gupta PN, Mishra V, Rawat A, et al. Non-invasive vaccine delivery in transfersomes, niosomes, and liposomes: a comparative study.
Int J Pharm. 2005;293(1–2):73–82.

6. Brown GD, Denning DW, Gow NA, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.

7. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multinational prevalence of fungal diseases—estimate precision. J Fungi (Basel). 2017;3(4):57.

8. Cowen LE, Sanglard D, Howard SJ, et al. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med.
2015;5(7):a019752.

9. Groll AH, Rijnders BJA, Walsh TJ, et al. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B.
Clin Infect Dis. 2019;68(Suppl_4):S260–S274.

10. Prabhu P, Kumar P, Koland M, et al. Nanoemulsion-based delivery system for improved oral bioavailability and therapeutic efficacy of clotrimazole. Colloids Surf B Biointerfaces.
2014;116:342–351.

11. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm.
2009;366(1–2):170–184.

12. Souto EB, Müller RH. Lipid nanoparticles: effect on bioavailability and pharmacokinetics of drugs. Int J Nanomedicine.
2008;3(4):785–796.

13. Tiwari G, Tiwari R, Bannerjee SK, et al. Drug delivery systems: an updated review. Int J Pharm Investig. 2012;2(1):2–11.

14. Balfour J. A., Faulds D. Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs.
1992;43(2):259–284.

15. Rissmann R., Groenink W., Weerheim A. M., et al. New ointment formulations for topical delivery of amphotericin B. Int J Pharm.
2008;362(1-2):20–28.

16. Crawford F., Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev.
2007;(3):CD001434.

17. Crawford F., Hart R., Bell-Syer S. E., Torgerson D. J. Athlete's foot treatments: Summary of

Cochrane review. BMJ.
2000;321(7273):1451–1454.

18. Elewski B. E. Onychomycosis: Pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415–429.

19. Pierard-Franchimont C., Pierard G. E. Ketoconazole shampoo: Focus on dandruff, seborrheic dermatitis, and androgenic alopecia.
Skin Pharmacol Appl Skin Physiol. 1998;11(5):285–289.

20. Southwick G. J., DeFelice D. L. Development and evaluation of a topical gel formulation of terbinafine. J Am Acad Dermatol.
1990;23(2 Pt 2):305–308.

21. Baran R., Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: An overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol.
2005;19(1):21–29.

22. Pappas P. G., Rex J. H., Sobel J. D., et al. Guidelines for treatment of candidiasis. N. Engl. J. Med. 2004;351(14):1441– 1452.
https://doi.org/10.1056/NEJMra040484

23. Vazquez J. A., Zawawi A. A., Sobel J. D. Miconazole mucoadhesive buccal tablet for treatment of oropharyngeal candidiasis in HIVinfected patients. N. Engl. J. Med.
2002;346(16):1228–1233. https://doi.org/10.1056/NEJMoa011906

24. Workowski K. A., Bolan G. A. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep.
2015;64(RR03):1–137. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm.

25. Farr A., Kiss H., Holzer I., et al. Oral versus vaginal treatment of vulvovaginal candidiasis: a prospective, randomized, double-blind study. BJOG.
2005;112(2):191–195. https://doi.org/10.1111/j.1471-0528.2004.00318.x

26. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 1999 Jan;12(1):40-79.
Doi:10.1128/CMR.12.1.40.